Antibody-Drug Conjugate for Advanced HER2-Positive Gastric Cancer Improves Outcomes
T-DXd treatment was associated with a better ORR and prolonged OS compared with standard chemotherapy with either irinotecan or paclitaxel.
News
Latest News
Approximately 30% of Anticancer Trials from 2006 to 2015 Reported Changes in Clinical Benefit Scores From Initial Approval
Clinical benefit scores of many anticancer medications approved during the study period seemed to improve at data follow-up.
Tucatinib-Containing Regimen Prolongs Overall Survival in Breast Cancer Characterized by Brain Metastases
Nearly half of the patients with advanced HER2-positive breast cancer enrolled in the randomized, phase II HER2CLIMB trial had disease that had metastasized to the brain.
Thirty Percent of Patients With NSCLC Who Had Actionable Variants Were Not Prescribed Targeted Therapies: Study
The VA NPOP is a program established to provide access to next-generation sequencing for veterans with advanced solid tumors.
Later Bedtime May Be Associated With Higher Levels of Pain in Ovarian Cancer Survivors
An analysis utilized the baseline characteristics of patients with pretreated ovarian cancer enrolled in a phase 3 trial to evaluate lifestyle interventions.
Anti-TIGIT Drug Improved Overall Response Rate, Progression-Free Survival in PD-L1-Selected NSCLC
Updated results confirmed benefit seen in primary analysis.
A Majority of Anticancer Drug Approvals Are Based on Trials With Core Limitations, Say Researchers
Core limitations were defined as lack of randomization, lack of overall survival data, inappropriate use of crossover, and use of suboptimal control arms.
Single, Priming Dose of Tremelimumab Plus Durvalumab Active in Second-Line Hepatocellular Carcinoma
Trememlimumab thought to induce immune response.
Pembrolizumab-Axitinib Continued to Offer Durable Benefits in Advanced RCC
Updated findings from KEYNOTE-426 showed that frontline pembrolizumab-axitinib continued to be associated with improved PFS and OS compared with sunitinib in advanced RCC.
Mirvetuximab Soravtansine Plus Bevacizumab in FRα-Overexpressing Advanced Epithelial Ovarian Cancer
This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.
Patient Relapse Time After Auto-HCT in Chemosensitive DLBCL Does Not Appear to Influence PFS
The data reinforce the need for direct comparison of CAR-T and autologous transplantation.
Dual-Targeting CAR-T Appears Active in R/R DLBCL
The Alexander study was designed to test if dual-targeting of CD19 and CD22 would reduce the likelihood of antigen escape.
Alpelisib Plus Fulvestrant Demonstrates Efficacy in PIK3CA-Mutated, HR+, HER2- Breast Cancer After CDK4/6 Inhibitor
PI3KCA is mutated in approximately 40% of patients with HR-positive, HER2-negative advanced breast cancer, and is associated with treatment resistance and poor outcomes.
Neoadjuvant Treatment of Borderline-Resectable Pancreatic Cancer Led to Improved Overall Survival
Neoadjuvant treatment with GEMCAP, FOLFIRINOX, or capecitabine plus radiotherapy prolonged OS compared with immediate surgery in patients with pancreatic cancer.
Deep and Durable Responses to Double Anti-BCMA, Single-Domain Antibody CAR-T Therapies Seen in RRMM
CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.
Want to read more?
Please login or register first to view this content.
